David L. Sutcliffe

David L. Sutcliffe

Auto-generated profile, based on publicly available information

David L. Sutcliffe

Division of Pediatric Cardiology, Children's Mercy Hospital, Kansas City, Missouri, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 November 2019 in ASAIO Journal
Verified
Journal Article
Closed access
CVChristina J. VanderPluym
Christina J. VanderPluym
RCRyan S. Cantor
Ryan S. Cantor
DMDesiree Machado
Desiree Machado
GBGerald Boyle
Gerald Boyle
LMLindsay May
Lindsay May
JCJennifer Conway
Jennifer Conway
Thrombotic and bleeding complications have historically been major causes of morbidity and mortality in pediatric ventricular assist device (VAD) support. Standard anticoagulation with unfractionated heparin is fraught with problems related to its heterogeneous biochemical composition and unpredictable pharmacokinetics. We sought to describe the utilization and outcomes in children with paracorporeal VAD support who are treated with direct thrombin inhibitors (DTIs) antithrombosis therapy. Retrospective multicenter review of all pediatric patients (aged <19 years) treated with a DTI (bivalirudin or argatroban) on paracorporeal VAD support, examining bleeding and thrombotic adverse events. From May 2012 to 2018, 43 children (21 females) at 10 centers in North America, median age 9.5 months (0.1–215 months) weighing 8.6 kg (2.8–150 kg), were implanted with paracorporeal VADs and treated with a DTI. Diagnoses included cardiomyopathy 40% (n = 17), congenital heart disease 37% (n = 16; single ventricle n = 5), graft vasculopathy 9% (n = 4), and other 14% (n = 6). First device implanted included Berlin Heart EXCOR 49% (n = 21), paracorporeal continuous flow device 44% (n = 19), and combination of devices in 7% (n = 3). Adverse events on DTI therapy included; major bleeding in 16% (n = 7) (2.6 events per 1,000 patient days of support on DTI), and stroke 12% (n = 5) (1.7 events per 1,000 patient days of support on DTI). Overall survival to transplantation (n = 30) or explantation (n = 8) was 88%. This is the largest multicenter experience of DTI use for anticoagulation therapy in pediatric VAD support. Outcomes are encouraging with lower major bleeding and stroke event rate than that reported in literature using other anticoagulation agents in pediatric VAD support.

1 June 2018 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Open access
DSDavid L. Sutcliffe
David L. Sutcliffe
EPElizabeth Pruitt
Elizabeth Pruitt
RCRyan S. Cantor
Ryan S. Cantor
JGJustin Godown
Justin Godown
JLJohn Lane
John Lane
EBElizabeth D. Blume
Elizabeth D. Blume
Pediatric ventricular assist device (VAD) support as bridge to transplant has improved waitlist survival, but the effects of pre-implant status and VAD-related events on post-transplant outcomes have not been assessed. This study is a linkage analysis between the PediMACS and Pediatric Heart Transplant Study databases to determine the effects of VAD course on post-transplant outcomes. Database linkage between October 1, 2012 and December 31, 2015 identified 147 transplanted VAD patients, the primary study group. The comparison cohort was composed of 630 PHTS patients without pre-transplant VAD support. The primary outcome was post-transplant survival, with secondary outcomes of post-transplant length of stay, freedom from infection and freedom from rejection. At implant, the VAD cohort was INTERMACS Profile 1 in 33 (23%), Profile 2 in 89 (63%) and Profile 3 in 14 (10%) patients. The VAD cohort was older, larger, and less likely to have congenital heart disease (p < 0.0001). However, they had greater requirements for inotrope and ventilator support and increased liver and renal dysfunction (p < 0.0001), both of which normalized at transplant after device support. Importantly, there were no differences in 1-year post-transplant survival (96% vs 93%, p = 0.3), freedom from infection (81% vs 79%, p = 0.9) or freedom from rejection (71% vs 74%, p = 0.87) between cohorts. Pediatric VAD patients have post-transplant outcomes equal to that of medically supported patients, despite greater pre-implant illness severity. Post-transplant survival, hospital length of stay, infection and rejection were not affected by patient acuity at VAD implantation or VAD-related complications. Therefore, VAD as bridge to transplant mitigates severity of illness in children.

1 February 2023 in Circulation: Heart Failure
Verified
Journal Article
Closed access
ALAdam M. Lubert
Adam M. Lubert
ACAri Cedars
Ari Cedars
CAChristopher S. Almond
Christopher S. Almond
SAShahnawaz Amdani
Shahnawaz Amdani
JCJennifer Conway
Jennifer Conway
KSKurt R. Schumacher
Kurt R. Schumacher
Individuals with Fontan circulation are at risk of late mortality from both cardiac and noncardiac causes. Despite the known risk of mortality, referral indications for advanced heart failure care vary between centers, and many individuals die from Fontan circulation-related complications either after late consideration for advanced heart failure therapies or having never seen a heart failure specialist. There is a critical need for guidelines to direct appropriately timed referral for advanced heart failure consultation. The Advanced Cardiac Therapies Improving Outcomes Network (ACTION) Fontan Committee has developed recommended thresholds for advanced heart failure referral to guide primary cardiologists. These recommendations are divided into 4 categories of clinical Fontan circulatory dysfunction including (1) cardiac/systemic ventricular dysfunction, (2) Fontan pathway dysfunction, (3) lymphatic dysfunction, and (4) extracardiac dysfunction.

27 May 2022 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
DGDipankar Gupta
Dipankar Gupta
NBNeha Bansal
Neha Bansal
BJByron C. Jaeger
Byron C. Jaeger
RCRyan C. Cantor
Ryan C. Cantor
DKDevin Koehl
Devin Koehl
DSDavid L. Sutcliffe
David L. Sutcliffe

18 January 2025 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
JEJonathan B Edelson
Jonathan B Edelson
ARAlexander Raskin
Alexander Raskin
MAMohammed Absi
Mohammed Absi
IAIki Adachi
Iki Adachi
OAOthman Aljohani
Othman Aljohani
ACAction Collaborators
Action Collaborators

19 September 2022 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
DNDeipanjan Nandi
Deipanjan Nandi
SAScott R. Auerbach
Scott R. Auerbach
NBNeha Bansal
Neha Bansal
HBHolger Buchholz
Holger Buchholz
JCJennifer Conway
Jennifer Conway
CVChet R. Villa
Chet R. Villa